{"id":"NCT02006641","sponsor":"H. Lundbeck A/S","briefTitle":"Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil","officialTitle":"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02","primaryCompletion":"2016-12","completion":"2016-12","firstPosted":"2013-12-10","resultsPosted":"2018-02-20","lastUpdate":"2018-02-20"},"enrollment":858,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Idalopirdine","otherNames":["Lu AE58054"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Idalopirdine 10 mg","type":"EXPERIMENTAL"},{"label":"Idalopirdine 30 mg","type":"EXPERIMENTAL"}],"summary":"To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).","primaryOutcome":{"measure":"Change in Cognition","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Placebo","deltaMin":0.64,"sd":0.39},{"arm":"Idalopirdine 10 mg","deltaMin":0.55,"sd":0.39},{"arm":"Idalopirdine 30 mg","deltaMin":1.27,"sd":0.39}],"pValues":[{"comp":"OG000 vs OG001","p":"1.000"},{"comp":"OG000 vs OG002","p":"0.2223"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":162,"countries":["United States","Argentina","Brazil","Canada","Croatia","Czechia","Estonia","Finland","France","Hungary","Ireland","Israel","Italy","Lithuania","Poland","Portugal","South Korea","Taiwan","United Kingdom"]},"refs":{"pmids":["31193334","30474567","29318278"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":282},"commonTop":["Accidental overdose"]}}